NEUROLOGICAL MOTOR CONTROL AND MOTOR CONTROL DISORDERS: RESTITUTIONOF FUNCTION NIH GUIDE, Volume 21, Number 3, Part II of II, January 24, 1992 PA: PA-92-36 P.T. 34 Keywords: Neuromuscular Disorders Neuroscience Neurophysiology Sensory System Electrophysiology Trauma, Cell Biology National Institute of Neurological Disorders and Stroke PURPOSE The National Institute of Neurological Disorders and Stroke (NINDS), a component of the National Institutes of Health (NIH), invites research grant applications through this Program Announcement (PA) for support of research on neurological motor control, motor control disorders, and the restitution of function. Applications covering a broad range of activities in the neurological sciences from basic research to clinical research are encouraged. It is expected that regardless of approach, all studies will be focused on normal and abnormal performance of the nervous system in regard to motor control. This type of solicitation is issued to encourage investigator-initiated research projects in areas of special programmatic interest to the NINDS. BACKGROUND The NINDS is the principal NIH component for support of basic and clinical research on the prevention, diagnosis, treatment, and rehabilitation of neurological disorders. Disorders in motor control occur as sequelae to many neurological and neuromuscular diseases and disorders. Understanding these disorders and approaches to restitution of function in patients with these disorders is difficult because many elements of the nervous system interact to produce motor control in healthy individuals. Motor control involves broad areas of the central nervous system including the spinal cord, the cerebellum, and motor areas of the cortex, basal ganglia, and thalamus among others. Sensory input is also an important element in motor control. In addition, it is being increasingly appreciated that nerve-muscle interactions and the intrinsic properties of muscles and tendons may play a significant role in motor control. The understanding of motor control necessary for appropriate treatment of its disorders requires a detailed understanding of the individual elements of motor control systems and, equally, an understanding of how the different components interact. This PA is issued to encourage grant applications that cover a broad range of motor disorders, areas of the nervous system, and levels of integration but that share the common focus of motor control and its disorders. RESEARCH GOALS AND SCOPE This announcement is issued to encourage and foster investigator-initiated basic, clinical, and applied research on motor control and its disorders. Examples of research objectives appropriate for inclusion in applications responsive to this PA include: o Studies of the neurophysiological foundation of motor control; o Studies of the biomechanics and neuromuscular physiology of motor control including conscious and automatic control in humans or animals; o Studies of the role of sensory systems in motor control; o Studies of the electrophysiological, neuroendocrine, and biochemical foundation of motor control; o Studies of the integration of motor, sensory, and central systems in gait, postural control, and fine motor control such as hand movements; o Studies of the neurological dysfunctions in motor control associated with cerebellar degeneration, hereditary ataxias, demyelinating disorders, such as multiple sclerosis, and in degenerative disorders such as Huntington's and Parkinson's disease; o Studies of abnormal nervous system functioning after viral infection, stroke, trauma, toxic insult, or in cerebral palsy and post-poliomyelitis syndrome; o Physiologic analysis of basic movement disorder mechanisms and symptomatology, e.g., chorea, dystonia, rigidity, spasticity, and tremor; o Applied research directed at improving or restoring motor control in neurologically impaired individuals; o Studies of neurological locomotor abnormalities in AIDS, neuropathies, atrophies, and other neurological diseases. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, Neurological Motor and Motor Control Disorders: Restitution of Function, is related to the priority area of chronic disabling conditions. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). MECHANISM OF SUPPORT The support mechanisms for this research will be the individual research grant (RO1), the First Independent Research Support and Transition (FIRST) Award (R29), Research Career Development Award (K04), Clinical Investigator Award (K08), and the program project grant (P01). The number of awards to be made is dependent upon receipt of a sufficient number of applications of high scientific merit and upon availability of funds. GENERAL REQUIREMENTS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Section 2, A-D of the Research Plan AND summarized in Section 2, E, Human Subjects. Applicants/offerers are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans (including American Indians or Alaska Natives), Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies. APPLICATION PROCEDURE Applications must be submitted on the grant application form PHS 398 (Rev. 10/88, reprinted 9/89) and will be accepted on any of the three receipt dates for research grant applications, February 1, June 1, and October 1. Application kits are available at most business and grants/contracts offices and may be obtained from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 496-7441. On the first (face) page, item 2, of the application, the word "yes" must be checked and the title and number of the announcement typed in the space provided: NEUROLOGICAL MOTOR CONTROL AND MOTOR CONTROL DISORDERS: RESTITUTION OF FUNCTION, PA-92-36. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. In such a case, a letter of agreement from either the GCRC program director or Principal Investigator must be included with the application. The original and six copies of the application must be sent or delivered to: Application Receipt Office Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** REVIEW PROCEDURES Applications will receive institute and initial review group (IRG) assignment on the basis of established Public Health Service referral guidelines. Applications will be reviewed for scientific and technical merit by an IRG. Following IRG review, the applications will receive a second-level review by an appropriate Council/Board. Applications will compete for available funds with all other approved applications assigned to the institute. REVIEW CRITERIA The standard review criteria will be used to assess the scientific merit of applications. The IRG will be reviewing the adequacy of protection of human subjects, the humane care of animals, and biosafety conditions. In clinical research studies, reviewers also will be evaluating the adequacy of the inclusion of women and minorities in the study populations. STAFF CONTACT Investigators are encouraged to contact: Dr. William Heetderks Division of Fundamental Neuroscience National Institute of Neurological Disorders and Stroke Federal Building, Room 9l6 Bethesda, MD 20892 Telephone: (301) 496-5745 Dr. A. P. Kerza-Kwiatecki Division of Demyelinating, Atrophic, and Dementing Disorders National Institute of Neurological Disorders and Stroke Federal Building, Room 804 Bethesda, MD 20892 Telephone: (301) 496-1431 Dr. Floyd J. Brinley, Jr. Division of Convulsive, Developmental, and Neuromuscular Disorders National Institute of Neurological Disorders and Stroke Federal Building, Room 816 Bethesda, MD 20892 Telephone: (301) 496-6541 Dr. Patricia A. Grady Division of Stroke and Trauma National Institute of Neurological Disorders and Stroke Federal Building, Room 8A10 Bethesda, MD 20892 Telephone: (301) 496-4226 For fiscal and administrative matters contact: Kathleen Howe Grants Management Specialist National Institute of Neurological Disorders and Stroke Federal Building, Room 1004 7550 Wisconsin Ave. Bethesda, MD 20892 Telephone: (301) 496-9231 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.854 - Biological Basis Research in Neurosciences, and 93.853 - Clinical Research related to Neurological Disorders. Grants will be awarded under the authority of the Public Health Service Act, Title III, Section 301 (Public Law 78-410, as amended; 42 USC 241) and administered under PHS grants policies and Federal Regulations at 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or a Health Systems Agency review. .
Return to NIH Guide Main Index
![]() |
Office of Extramural Research (OER) |
![]() |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
![]() |
Department of Health and Human Services (HHS) |
![]() |
||||